Is screening the BRCA +ve cost-effective?

Should BRCA-Positive Women Undergo Regular Ovarian Cancer Screening?

Study Reference: Review Article / Clinical Debate; Cancer Network (2026)

Women carrying BRCA mutations face an elevated risk of developing ovarian cancer; the National Comprehensive Cancer Network (NCCN) in the US recommends screening every 6 months, using imaging and serology. However, this intensive approach is costly and consumes limited resources. Dr Beth Karlan from Cedars-Sinai strongly supports routine screening, arguing that early detection promotes survival and citing incomplete studies with promising results. Conversely, Dr Michael Birrer from Boston opposes routine screening, emphasising that CA-125 serology is notoriously unreliable in younger women, and noting that because most high-grade serous cancers originate in the fallopian tubes, our understanding of the natural history of the disease remains incomplete.

Key Points

  • Elevated Genetic Risk: Women harbouring BRCA pathogenic variants carry a markedly increased risk of developing hereditary breast and ovarian cancer syndromes.

  • The Pro-Screening perspective: Proponents, such as Dr Karlan, argue that regular 6-monthly imaging and biomarker testing can catch tumours earlier, potentially improving survival outcomes based on emerging trial data.

  • The alternate viewpoint: Critics, such as Dr Birrer, caution that serum markers like CA-125 lack diagnostic reliability in premenopausal or younger women and fail to account for rapid-onset interval cancers.

  • Tubal Origin Complication: Recognition that high-grade serous cancers frequently initiate in the fallopian tubes (rather than slowly evolving on the ovarian surface) calls into question whether standard imaging and blood tests can effectively intercept the disease.

  • Resource and Cost Implications: Intensive surveillance models place a heavy financial burden on healthcare systems and consume limited diagnostic resources without definitive proof of mortality reduction.

What This Means for Ovarian Cancer Support Nurses

Clinical ChallengePractical Action 
Different adviceReassure callers with BRCA mutations who feel conflicted; explain that while surveillance protocols exist, screening remains controversial among top specialists.
Explaining Risk-Reducing SurgeryHelp patients understand why major guidelines generally view risk-reducing bilateral salpingo-oophorectomy (rather than serial screening) as the gold-standard preventive strategy for BRCA carriers.
Addressing Test UnreliabilitySupport callers by clarifying why CA-125 blood tests and ultrasounds can be unreliable or give false reassurance, particularly in younger women or rapidly developing tubal malignancies.

Tags: #OvarianCancer #BRCA #GeneticTesting #ScreeningControversy #PreventativeOncology #SupportNursing

Comments

Post a Comment

Popular posts from this blog

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more

Fatal blood clot

Image
Cancer-associated thrombosis in the era of precision oncology: Mechanisms, challenges and future directions https://tinyurl.com/52e2xt9p For people with cancer the risk of dying from other causes is increased. The most likely non- cancer cause of death is from thrombosis . Either arterial clot with possible stroke or infarct or venous clot with subsequent pulmonary embolus . Death from thrombosis is up to 12 times more likely for patients with cancer compared to the general population especially early, during chemo. This review describes why cancer patients are at high risk of thrombos is; it appears there are two groups of cancers those which are at high risk of thrombosis which includes ovarian cancer patients who have a 20% risk , and those which are relatively low risk, breast cancer is in this group. Thrombosis is a result of slow blood flow, vascular damage or increased clotting factors. Cancer increases all these hazards with some specific issues such as , platelet adh...
Read more

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more